FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT (OF CHANGES II	N BENEFICIAL	OWNERSHIP
-------------	---------------	--------------	-----------

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	ourden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Rhode Peter					2. Issuer Name and Ticker or Trading Symbol HCW Biologics Inc. [HCWB]								Relationship leck all appli Directo	cable) or	Persor	10% Ow	ner	
(Last)	(F W BIOLOG	*	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 11/17/2023								Cofficer (give title below) See Remarks Other (specify below)				
2929 N. COMMERCE PARKWAY					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	AR FI	L	33025												iled by One iled by More		Ü	- 1
(City) (State) (Zip)					Rı	Rule 10b5-1(c) Transaction Indication												
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										to								
		Tab	le I - Non	-Deriv	ativ	e Se	curit	ies Ac	quired	, Dis	posed o	of, or Be	neficial	ly Owned				
1. Title of Security (Instr. 3) 2. Trans: Date (Month/L				Execution Date,		Code	Transaction Disposed Of (D) (Instr. 3, 4			Benefici Owned	es ally Following	6. Owner Form: I (D) or II (I) (Inst	Direct c ndirect E r. 4) C	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) o (D)	Price	Transac	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock 11/17				7/202	7/2023		М		15,00	15,000 A S		4 63,500		Ι)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any		Date,	Fransaction of Code (Instr. De S) Se Ac (A Di of		of E		Expiration	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly D	0. Ownership Form: Oirect (D) r Indirect) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares					
Stock Option Grant (Right to Buy)	\$0.14	11/17/2023			М			15,000	(1)	1	2/19/2029	Common Stock	15,000	\$0.00	36,427		D	

Explanation of Responses:

1. These option shares were part of a stock option grant covering 85,713 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant vested on May 30, 2022; and 35% of the total shares subject to the stock option grant vested on May 30, 2022; and 35% of the total shares subject to the stock option grant vested on May 30, 2023, subject to the reporting person's continuous service through the applicable vesting date.

Remarks

Title of the Officer: Chief Scientific Officer and Vice President of Clinical Operations.

/s/ Nicole Valdivieso, as

Attorney-in-Fact for Peter

11/20/2023

Rhode

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.